Genetic
ctDNA Testing
ctDNA Testing is a genetic therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Completed1
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (50.0%)
N/A1 (50.0%)
Trials by Status
completed133%
not_yet_recruiting133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingnot_applicable
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NCT07270666
not_yet_recruitingphase_2
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
NCT07058012
completed
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer
NCT05079074
Clinical Trials (3)
Showing 3 of 3 trials
NCT07270666Not Applicable
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NCT07058012Phase 2
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
NCT05079074
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 3